Journey Medical Corp SEC Filings

Journey Medical Corporation (DERM) filed a Form 4 reporting that director Miranda Jayne Toledano received an equity award on 25 June 2025.

• Grant: 7,173 restricted stock units (RSUs) under the 2015 Stock Plan at a grant price of $0.
• Vesting: The RSUs will vest in full on 25 June 2026.
• Post-grant ownership: Toledano now beneficially owns 88,618 Journey Medical common shares, including unvested RSUs, all held directly.

No shares were sold or otherwise disposed of, and no derivative securities were involved. The filing, signed by attorney-in-fact Ramsey Alloush on 07 July 2025, represents a routine director compensation event rather than an open-market transaction.

Journey Medical Corp. (DERM) – Form 4 insider transaction

On June 25 2025, Director Dr. Lindsay A. Rosenwald received 7,173 restricted stock units (RSUs) at a cost of $0 under the company’s 2015 Stock Plan. The RSUs will vest in full on June 25 2026.

After this grant, Dr. Rosenwald beneficially owns 161,146 shares directly and 176,470 shares indirectly through a limited-liability company of which she is the managing member—an aggregate of 337,616 common shares. No shares were sold, and no derivative securities were involved.

The filing reflects routine equity compensation intended to align the director’s interests with shareholders. The grant size is modest relative to typical daily trading volume and does not materially affect the company’s share count or control structure.

Journey Medical Corp (DERM) – Form 4 insider filing: Director Michael Cooper Pearce was granted 7,173 restricted stock units (RSUs) on 25 Jun 2025 under the company’s 2015 Stock Plan. The award was issued at no cost and will vest in full on 25 Jun 2026. After the grant, Pearce’s direct beneficial ownership rose to 37,173 shares, which includes previously awarded RSUs that vest over various schedules. No open-market purchases or sales occurred, and there was no cash consideration. The transaction is routine equity compensation intended to align the director’s interests with shareholders, with only immaterial dilution to existing holders.

Journey Medical (NASDAQ:DERM) filed an 8-K detailing the June 24, 2025 annual meeting results and a Fourth Amended & Restated Certificate of Incorporation. Stockholders owning 85.0% of voting power approved three items:

• Election of six directors for one-year terms
• Ratification of KPMG LLP as 2025 auditor (32,468,451 for; 10,433 against)
• Adoption of the amended charter, which now exculpates corporate officers from certain personal liability

Total votes for the charter change were 25,373,988 for and 798,994 against, with 10,387 abstentions and 6,319,771 broker non-votes. The filing is effective upon Delaware acceptance and is furnished as Exhibit 3.1.

Journey Medical Corporation (NASDAQ: DERM) filed an 8-K reporting its forthcoming inclusion in the Russell 2000 and Russell 3000 indices, effective after the U.S. market close on June 27 2025. The change follows FTSE Russell’s annual reconstitution and does not involve any new financial results or transactions. Index inclusion typically increases stock visibility and can lead to incremental demand from passive funds benchmarked to the Russell family. The company attached the related press release as Exhibit 99.1; no other operational or financial updates were disclosed.

Form 4 filing highlights

Journey Medical Corp. (DERM) filed a Form 4 indicating that Chief Operating Officer Ramsey Alloush received two equity awards on 17 June 2025 under the company’s 2015 Stock Plan.

Awards granted

• 46,863 restricted stock units (RSUs) acquired at $0 cost.
• 62,795 stock options with a $6.31 exercise price, expiring 17 June 2035.

Vesting schedule

• RSUs: 15,621 shares vest on 1 Jan 2026; 15,621 on 1 Jan 2027; 15,621 on 1 Jan 2028.
• Options: 20,932 shares vest on 1 Jan 2026; 20,932 on 1 Jan 2027; 20,931 on 1 Jan 2028.

Post-grant, Alloush directly owns 551,680 common shares (including unvested RSUs). Transaction code “A” confirms the awards were grants, not open-market trades.

Investor takeaways

The disclosure represents routine executive compensation designed to align management with shareholders. While there is no immediate cash outlay or share purchase, up to 109,658 additional shares could enter the float over the next three years as the RSUs settle and options are exercised, causing minor dilution. Overall, the filing is informational and does not signal a change in the company’s operating or financial outlook.